Cargando…

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease

The N-terminally truncated pyroglutamate Aβ(3−42) (Aβ(pE3−42)) and Aβ(4−42) peptides are known to be highly abundant in the brain of Alzheimer's disease (AD) patients. Both peptides show enhanced aggregation and neurotoxicity in comparison to full-length Aβ, suggesting that these amyloid peptid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez-Noguerola, Jose S., Giessen, Nicolai M. E., Ueberück, Maximilian, Meißner, Julius N., Pelgrim, Charlotte E., Adams, Johnathan, Wirths, Oliver, Bouter, Yvonne, Bayer, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852075/ https://www.ncbi.nlm.nih.gov/pubmed/29568268 http://dx.doi.org/10.3389/fnagi.2018.00064

Ejemplares similares

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
por: Wirths, Oliver, et al.
Publicado: (2009)

N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits
por: Bouter, Yvonne, et al.
Publicado: (2013)

Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways
por: Dammers, C., et al.
Publicado: (2017)

Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β(3-42) peptide
por: Cho, Illhwan, et al.
Publicado: (2023)

Activity and Architecture of Pyroglutamate-Modified Amyloid-β (Aβ(pE3-42)) Pores
por: Gillman, Alan L., et al.
Publicado: (2014)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
por: Shahpasand-Kroner, Hedieh, et al.
Publicado: (2018)

Synaptic Alterations in Mouse Models for Alzheimer Disease—A Special Focus on N-Truncated Abeta 4-42
por: Dietrich, Katharina, et al.
Publicado: (2018)

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
por: Bayer, Thomas A.
Publicado: (2021)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

A critical role for the self-assembly of Amyloid-β1-42 in neurodegeneration
por: Marshall, Karen E., et al.
Publicado: (2016)

Novel Neuroprotective Function of Apical-Basal Polarity Gene Crumbs in Amyloid Beta 42 (Aβ42) Mediated Neurodegeneration
por: Steffensmeier, Andrew M., et al.
Publicado: (2013)

TGF-β1 Protection against Aβ(1–42)-Induced Neuroinflammation and Neurodegeneration in Rats
por: Shen, Wei-Xing, et al.
Publicado: (2014)

Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau
por: Zampar, Silvia, et al.
Publicado: (2021)

N-Acetyltransferase 9 ameliorates Aβ42-mediated neurodegeneration in the Drosophila eye
por: Deshpande, Prajakta, et al.
Publicado: (2023)

Reduced Acoustic Startle Response and Prepulse Inhibition in the Tg4-42 Model of Alzheimer’s Disease
por: Sichler, Marius E., et al.
Publicado: (2019)

Analysis of Motor Function in the Tg4-42 Mouse Model of Alzheimer’s Disease
por: Wagner, Jannek M., et al.
Publicado: (2019)

Nonphosphorylated tau slows down Aβ(1–42) aggregation, binds to Aβ(1–42) oligomers, and reduces Aβ(1–42) toxicity
por: Beeg, Marten, et al.
Publicado: (2021)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Amyloid-β 1–24 C-terminal truncated fragment promotes amyloid-β 1–42 aggregate formation in the healthy brain
por: Mazzitelli, Sonia, et al.
Publicado: (2016)

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
por: Antonios, Gregory, et al.
Publicado: (2015)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Protection of TGF-β1 against Neuroinflammation and Neurodegeneration in Aβ(1–42)-Induced Alzheimer’s Disease Model Rats
por: Chen, Jia-Hui, et al.
Publicado: (2015)

Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42
por: Song, Chuli, et al.
Publicado: (2022)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

Trans-Chalcone Plus Baicalein Synergistically Reduce Intracellular Amyloid Beta (Aβ(42)) and Protect from Aβ(42) Induced Oxidative Damage in Yeast Models of Alzheimer’s Disease
por: Dhakal, Sudip, et al.
Publicado: (2021)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

The synergy of β amyloid 1-42 and oxidative stress in the development of Alzheimer’s disease-like neurodegeneration of hippocampal cells
por: Karapetyan, Gohar, et al.
Publicado: (2022)

Short Aβ peptides attenuate Aβ42 toxicity in vivo
por: Moore, Brenda D., et al.
Publicado: (2018)

Microarray Analysis on Human Neuroblastoma Cells Exposed to Aluminum, β(1–42)-Amyloid or the β(1–42)-Amyloid Aluminum Complex
por: Gatta, Valentina, et al.
Publicado: (2011)

Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function
por: Barucker, Christian, et al.
Publicado: (2015)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
por: Cynis, Holger, et al.
Publicado: (2016)

Effect of Lauric Acid on the Stability of Aβ(42) Oligomers
por: Khatua, Prabir, et al.
Publicado: (2021)

Misfolded amyloid-β-42 impairs the endosomal–lysosomal pathway
por: Marshall, Karen E., et al.
Publicado: (2020)

N-Terminally Truncated and Pyroglutamate-Modified Aβ Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer’s Disease
por: Domingo, Guido, et al.
Publicado: (2021)

Capping of Aβ42 Oligomers by Small Molecule Inhibitors
por: Fu, Ziao, et al.
Publicado: (2014)

Influence of denaturants on amyloid β42 aggregation kinetics
por: Weiffert, Tanja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2tamf8h08jav5pn4bjshje0gi8